Trial Profile

Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabigatran etexilate (Primary) ; Aspirin; Warfarin
Indications Cerebral infarction
Focus Therapeutic Use
Acronyms DECISIVE

Most Recent Events

15 Nov 2021 Primary endpoint of composite of clinical cerebral infarct or new cerebral MRI lesions has not been met, according to results presented at the American Heart Association Scientific Sessions 2021.
15 Nov 2021 Results presented at the American Heart Association Scientific Sessions 2021
11 Jan 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com